The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:
-- The first section of this topic is shown below --
- Historically, nausea was one of the most debilitating side effects of chemotherapy. The advent and use of effective antiemetic therapies have made chemotherapy much more tolerable for cancer patients.
- Incidence of chemotherapy-induced nausea and vomiting (CINV) is widely variable and depends on both drug and dose used.
- CINV can be categorized as acute (<24 hours) or delayed (>24 hours). Acute CINV is an important predictor of delayed CINV.
- Prevention of CINV is more effective than treatment. Commonly used prophylactic agents include:
- Dexamethasone, which has active antiemetic properties. It is frequently administered via IV before chemotherapy (premedication) and continued orally for 2–3 days with certain chemotherapy regimens.
- 5-Hydroxytryptamine-3 (5-HT3) receptor antagonists (ondansetron, granisetron, dolasetron, palonosetron), which are highly effective and widely used as premedications.
- Aprepitant, which is used with highly emetogenic regimens.
- Olanzapine, an antipsychotic agent, is also effective in preventing and managing CINV associated with highly emetogenic regimens.